Methotrexate-resistant form of dihydrofolate reductase protects transgenic murine embryos from teratogenic effects of methotrexate

Pediatric and Developmental Pathology

Volumn 1, Issue 6, 1998, Pages 503-512

  Sutton, Cari ^a   Mcivor, R Scott ^b   Vagt, Micki ^b   Doggett, Barbara ^a   Kapur, Raj P ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Amethopterin; Aminopterin; Ectrodactyly; Frontonasal dysplasia; Malformation; Teratogen; Vascular disruption

Indexed keywords

DIHYDROFOLATE REDUCTASE; ENZYME INHIBITOR; METHOTREXATE; TERATOGENIC AGENT;

ANIMAL; ARTICLE; CELL COUNT; COMPARATIVE STUDY; CONGENITAL MALFORMATION; CULTURE TECHNIQUE; CYTOLOGY; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; FORELIMB; GENE EXPRESSION REGULATION; GENETICS; HINDLIMB; LIMB BUD; MALE; METABOLISM; MOUSE; PREGNANCY; TAIL; TRANSGENIC MOUSE;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; CELL COUNT; CULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; FORELIMB; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HINDLIMB; LIMB BUD; MALE; METHOTREXATE; MICE; MICE, TRANSGENIC; PREGNANCY; TAIL; TERATOGENS; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 0032199722     PISSN: 10935266     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100249900069     Document Type: Article

References (43)

1. Huennekens FM. The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. Adv Enzyme Regul 1994;34:397-419.
2. Chabner BA, Allegra CJ, Curt GA, Calabresi P. Antineoplastic agents. In: Goodman, Gilman, eds. The Pharmacological Basis of Therapeutics, 9th ed. New York: MacMillan, 1996;1243-1247.
3. Wise CM, Vuyyuru S, Roberts WN. Methotrexate in nonrenal lupus and undifferentiated connective tissue disease - a review of 36 patients. J Rheumatol 1996;23:1005-1010.
4. Gansauge S, Breitbart A, Rinaldi N, Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosis. Ann Rheum Dis 1997;55:382-385.
5. Dayan M, Segal R, Mozes E. Cytokine manipulation by methotrexate treatment in murine experimental systemic lupus erythematosis. J Rheumatol 1997;24:1075-1082.
6. Skalko RG, Gold MP. Teratogenicity of methotrexate in mice. Teratology 1974;9:159-164.
7. Hausknecht RV. Methotrexate and misoprostol to terminate early pregnancy. N Engl J Med 1995;333:537-540.
8. Grimes DA. Medical abortion in early pregnancy: a review of the evidence. Obstet Gynecol 1997;89:790-796.
9. Feldkamp M, Carey JC. Clinical teratology counseling and consultation case report: low dose methotrexated exposure in the early weeks of pregnancy. Teratology 1993;47:533-539.
10. Donnenfeld AE, Pastuszak A, Salkoff NJ, Schick B, Rose NC, Koren G. Methotrexate exposure prior to and during pregnancy. Teratology 1994;49:79-81.
11. Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990;88:589-592.
12. Milunsky A, Graef JW, Gaynor MF. Methotrexate-induced congenital malformations. J Pediatr 1968;72:790-795.
13. Warkany J. Aminopterin and methotrexate: folic acid deficiency. Teratology 1978;17:353-358.
14. Aviles A, Diaz-Maqueo JC, Talavera A, Guzman R, Garcia EL. Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 patients. Am J Hematol 1991;36:243-248.
15. 51chromium release assay. Teratology 1990;41:211-221.
16. Berry CL. Transient inhibition of DNA synthesis by methotrexate in the rat embryo and fetus. J Embryol Exp Morphol 1971;26:469-474.
17. DeSesso JM, Jordan RL. Drug-induced limb dysplasias in fetal rabbits. Teratology 1977;15:199-212.
18. DeSesso JM, Goeringer GC. Amelioration by leucovorin of methotrexate developmental toxicity in rabbits. Teratology 1991;43:201-205.
19. DeSesso JM, Goeringer GC. Methotrexate-induced develop-mental toxicity in rabbits is ameliorated by 1-(p-tosyl)-3,4,4-trimethylimidazolidine, a functional analog for tetrahydrofolate-mediated one-carbon transfer. Teratology 1992;45: 271-283.
20. Darab DJ, Minkoff R, Sciote J, Sulik KK. Pathogenesis of median facial clefts in mice treated with methotrexate. Teratology 1987;36:77-86.
21. Jordan RL, Wilson JG, Schumacher HJ. Embryotoxicity of the folate antagonist methotrexate in rats and rabbits. Teratology 1977:15:73-79.
22. Hoyme HE, Jones KL, Dixon SD, et al. Prenatal cocaine exposure and fetal vascular disruption. Pediatrics 1990;85: 743-747.
23. Fantel AG, Barber CV, Mackler B. Ischemia/reperfusion: a new hypothesis for the developmental toxicity of cocaine. Teratology 1992;46:285-292.
24. Chen C, Fen-fen L, Sheau-Wen J, Shuan-Pei L, Chung-Chi L. CVS exposed limb deficiency defects with or without other birth defects: presentation of 6 cases during a period of nine years. Am J Med Genet 1996;63:447-453.
25. Luijsterburg AJ, van-der-Zee DC, Gaillard JL, et al. Chorionic villus sampling and end-artery disruption of the fetus. Prenat Diagn 1997;17:71-76.
26. Simonsen CC, Levinson AD. Isolation and expression of an altered mouse dihydrofolate reductase cDNA. Proc Natl Acad Sci USA 19S3;80:2495-2499.
27. Haber DA, Beverly SM, Kiely ML, Schimke RT. Properties of an altered dihydrofolate reductase encoded by amplified genes in culture mouse fibroblasts. J Biol Chem 1981;256: 9501-9510.
28. Morris JA, May C, Kim HS, et al. Comparative methotrexate resistance of transgenic mice expressing two distinct dihydrofolate reductase variants. Transgenics 1996;2:53-67.
29. May C, Gunther R, McIvor RS. Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity. Blood 1995;86:2439-2448.
30. Isola LM, Gordon JW. Systemic resistance to methotrexate in transgenic mice carrying a mutant dihydrofolate reductase gene. Proc Natl Acad Sci USA 1986;83:9621-9625.
31. Morris JA, Mclvor RS. Saturation mutagenesis at dihydrofolate reductase codons 22 and 31: a variety of amino acid substitutions conferring methotrexate-resistance. Biochem Pharmacol 1994;47:1207-1220.
32. 22 variant of murine DHFR: protection of transgenic marrow transplant recipients from lethal doses of methotrexate. Exp Hematol 1997;25:1286-1295.
33. Brent RL. Relationship between uterine vascular clamping, vascular disruption syndrome, and cocaine teratogenicity. Teratology 1990;41:757-760.
34. Danielsson BR, Reiland S, Rundqvist E, Danielson M. Digital defects induced by vasodilating agents: relationship to reduction in uteroplacental blood flow. Teratology 1989; 40:351-358.
35. Van Allen MI. Structural anomalies resulting from vascular disruption. Pediatr Clin North Am 1992;39:255-277.
36. Millicovsky G, DeSesso JM. Differential embryonic cardiovascular responses to acute maternal uterine ischemia: an in vivo microscopic study of rabbit embryos with either intact or clamped umbilical cords. Teratology 1980;22:335-343.
37. Millcovsky G, DeSesso JM, Kleinman LI, Clark KE. Effects of hydroxyurea on hemodynamics of pregnant rabbits: a maternally mediated mechanism of embryotoxicity. Am J Obstet Gynecol 140:747-781.
38. Petter C, Bourbon J, Maltier J-P, Jost A. Simultaneous prevention of blood abnormalities and hereditary congenital amputations in a brachydactylous rabbit stock. Teratology 1977;15:149-158.
39. Kapur RP, Hoyle GW, Mercer EH, Brinster RL, Palmiter RD. Some neuronal cell populations express human dopamine β-hydroxylase-lacZ transgenes transiently during embryonic development. Neuron 1991;7:717-727.
40. Jegalian BG, Miller RW, Wright CV, Blum M, De Robertis EM. A Hox 3.3-lacZ transgene expressed in developing limbs. Mech Dev 1992;39:171-180.
41. Liu Y-H, Ma L, Wu L-Y, et al. Regulation of the Msx2 homeobox gene during mouse embryogenesis: a transgene with 439 bp of f5′ flanking sequence is expressed exclusively in the apical ectodermal ridge of the developing limb. Mech Dev 1994;48:187-197.
42. Shida MM, Jackson-Grusby LL, Ross SR, Linzer DIH. Placental-specific expression from the mouse placental lacogen II gene promoter. Proc Natl Acad Sci USA 1992;89: 3864-3868.
43. Sabath DE, Spangler EA, Rubin EM, Stamatoyannopoulos G. Analysis of the human zeta-globin gene promoter in transgenic mice. Blood 1993;82:2899-2905.